Alpha Teknova EPS TKNO
Diluted earnings per share by quarter and over the last twelve months, from 2020.
- Last 12 months, to Jun 30, 2026
- −$0.31
- Latest quarter, Q2 FY26
- −$0.06
- Fiscal year 2025
- −$0.33
Alpha Teknova's earnings per share was −$0.31 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.06.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$0.33 | n/a |
| FY2024 | −$0.59 | n/a |
| FY2023 | −$1.16 | n/a |
| FY2022 | −$1.69 | n/a |
| FY2021 | −$0.95 | −733% |
| FY2020 | $0.15 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.06 | n/a | −$0.31 | |
| Q1 FY26 | −$0.08 | n/a | −$0.32 | |
| Q4 FY25 | −$0.09 | n/a | −$0.33 | |
| Q3 FY25 | −$0.08 | n/a | −$0.35 | |
| Q2 FY25 | −$0.07 | n/a | −$0.42 | |
| Q1 FY25 | −$0.09 | n/a | −$0.48 | |
| Q4 FY24 | −$0.11 | n/a | −$0.59 | |
| Q3 FY24 | −$0.15 | n/a | −$0.74 | |
| Q2 FY24 | −$0.13 | n/a | −$0.93 | |
| Q1 FY24 | −$0.20 | n/a | −$1.05 | |
| Q4 FY23 | −$0.26 | n/a | −$1.16 | |
| Q3 FY23 | −$0.34 | n/a | −$1.37 |
Against its peers
Companies in Healthcare nearest Alpha Teknova's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| TKNOAlpha Teknova | −$0.31 | |
| VMDViemed Healthcare | $0.36 | +6% a year |
| EMBCEmbecta | $1.47 | +3% a year |
| INFUInfuSystem | $0.41 | +78% a year |
| ARVNArvinas | $0.16 | |
| NRCNRC Health | $0.25 | −67% a year |
| UTMDUtah Medical Products | $3.28 | −12% a year |
| TCMDTactile Systems Technology | $1.08 | +74% a year |
| ELMDElectromed | $1.31 | +56% a year |
| SBCSBC Medical | $0.47 | +47% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| Peer median | $0.74 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Alpha Teknova
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.